Brief: Janux Therapeutics Reports First Quarter 2023 Financial Results And Business Highlights

Janux Therapeutics

09/05/2023 21:31

May 9 (Reuters) - Janux Therapeutics Inc  JANX.O :
    * JANUX THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND BUSINESS HIGHLIGHTS
    * INTERIM CLINICAL UPDATE FROM PHASE 1 TRIAL OF JANX007
EXPECTED
IN 2H 2023
    * $316.9 MILLION IN CASH AND CASH EQUIVALENTS AND SHORT-TERM
INVESTMENTS AT END OF Q1 2023
    * FIRST PATIENT DOSED WITH EGFR-TRACTR (JANX008) IN
FIRST-IN-HUMAN
PHASE 1 CLINICAL TRIAL IN PATIENTS WITH SOLID TUMORS
    * QTRLY LOSS PER SHARE $0.42
    * Q1 EARNINGS PER SHARE VIEW $-0.49 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nBw6lHRzTa 
Further company coverage:  JANX.O 

 ((Reuters.Briefs@thomsonreuters.com;))